

**U-CyTech BV**

Yalelaan 48  
3584 CM Utrecht  
The Netherlands  
P +31.30.253 5960  
F +31.30.253 9344  
INFO@ucytech.com  
www.ucytech.com

**Data sheet ICE Peptide Pool**

*Peptide pool of 32 HLA class I-restricted T cell epitopes of human Influenza A virus, Cytomegalovirus and Epstein-Barr virus.*

**Cat. No.:** CT387

**Specificity:** To be used as an antigen-specific positive control in the human IFN- $\gamma$  ELISPOT assay. The pool consist of 32 peptides of Influenza A virus (Flu), Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) epitopes which are recognized by CD8<sup>+</sup> T cells and presented by 11 class I HLA-A and HLA-B alleles prevalent among Caucasian individuals.  
(Reference: Currier, J.R. *et al.* 2002. J. Immunol. Methods 260: 157-172)

The peptide pool can also be used as positive control in the human IL-2 and Granzyme B ELISPOT assay.

**Application:** Reconstitute the lyophilized contents by injecting 250  $\mu$ l of sterile distilled water into the vial. Mix the solution gently for approximately 15 seconds and allow it to stand for 2 minutes at room temperature. Avoid vigorous shaking.

Working concentration: 40x in culture medium containing human PBMC.  
Recommended peptide concentration: 0.5  $\mu$ g peptide/ml culture medium.  
Recommended cell concentration:  $2 \times 10^5$  human PBMC/well.  
Recommended culture volume in ELISPOT plate: 100  $\mu$ l/well.

**Contents:** Lyophilized ICE peptide pool. 32 x 5  $\mu$ g peptide/vial.  
Buffer prior to lyophilization: 0.25 ml PBS + 125 mM trehalose.  
Preservative free.

**Contained peptides:** VSDGGPNLY (Influenza A, HLA-A1), CTELKLSDY (Influenza A, HLA-A1), GILGFVFTL (Influenza A, HLA-A2), FMYSDFHFI (Influenza A, HLA-A2), CLGGLTMV (EBV, HLA-A2), GLCTLVAML (EBV, HLA-A2), NLVPMVATV (HCMV, HLA-A2), KTGGPYIKR (Influenza A, HLA-A68), RVLSEFIKGTK (Influenza A, HLA-A3), ILRGSVAHK (Influenza A, HLA-A3), RVRAYTYSK (EBV, HLA-A3), RLRAEAQVK (EBV, HLA-A3), SIIPSGPLK (Influenza A, HLA-A3/A11/A6), AVFDRKSDAK (EBV, HLA-A11), IVTDFSVIK (EBV, HLA A11), ATIGTAMYK (EBV, HLA-A11), DYC NVLNKEF (EBV, HLA-A24), LPFDKTTVM (Influenza A, HLA-B7), RPIFIRRL (EBV, HLA-B7), ELRSRYWAI (Influenza A, HLA-B8), RAKFKQLL (EBV, HLA-B8), FLRGRAYGL (EBV, HLA-B8), QAKWRLQTL (EBV, HLA-B8), SDEEEAIVAYTL (HCMV, HLA-B18), SRYWAIRTR (Influenza A, HLA-B27), ASCMGLIY (Influenza A, HLA-B27), RRIYDLIEL (EBV, HLA-B27), YPLHEQHGM (EBV, HLA-B35), IPSINVHHY (HCMV, HLA-B35), EENLLDFVRF (EBV, HLA-B44), EFFWDANDIY (HCMV, HLA-B44), TPRVTGGGAM (HCMV, HLA-B7).

**Sterility:** Membrane filtered (0.2  $\mu$ m).

**Packaging:** 5 ml glass bottle.

**Storage:** The lyophilized peptide pool can be safely stored at 4 °C for a defined length of time (expiry date indicated on vial).  
After reconstitution, it is strongly recommended to divide the reconstituted peptides into small aliquots for single use. These aliquots should be stored at  $\leq -20$  °C. Under these conditions the peptides are stable for minimal two years.

**General:** A white pancake-like powder.  
After reconstitution: a clear solution. Do not use if the solution is or has become turbid.

**Safety:** The product is not classified as hazardous according to Regulation (EC) no. 1272/2008.  
Consult the material safety data sheet (MSDS) for further information regarding hazards and safe handling practices. The MSDS can be found on our website [www.ucytech.com](http://www.ucytech.com).

